Poseida's Focus in Cell Therapy: Fully Allogeneic Approach

Poseida Therapeutics is focusing on a fully allogeneic approach in cell therapy. They initially worked on autologous CAR-T cell therapies but quickly shifted towards allogeneic approach. They now have three clinical stage programs, two in hematological malignancies and one in solid tumors. Their goal in 2024 is to execute and advance their pipeline in clinical development, while maintaining their unique culture at Poseida. They also emphasize the importance of their manufacturing capabilities, as they have their own clinical manufacturing facility to support all their programs.